Method for detecting content of main drug in phenoxyacetic acid drug
Detection of the main drug content of phenoxyacetic acid drugs through high performance liquid chromatography solves the problem of insufficient efficiency and accuracy of detection methods in the prior art, and provides a simple and accurate method suitable for drug quality control and Drug safety assessment.
Patent Information
- Application Number
- CN202410967480.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-29
AI Technical Summary
There is a lack of efficient and convenient detection methods in the prior art to determine the main drug content of phenoxyacetic acid drugs, especially in terms of drug quality control and drug safety.
Using high performance liquid chromatography, the drug effect components are calculated by preparing test and reference solutions, combined with UV detector and specific chromatographic column conditions, and phosphate buffer-acetonitrile as mobile phase. content.
It realizes the rapid and accurate determination of the main drug content in phenoxyacetic acid drugs, improves detection efficiency, is characterized by simple operation, high reproducibility and good accuracy, meets the requirements of the drug analysis method of the Chinese Pharmacopoeia, and has important applications value.
Smart Images

Figure BDA0004952176450000041 
Figure BDA0004952176450000051 
Figure BDA0004952176450000061
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and particularly relates to a method for detecting the content of a main drug in a phenoxyacetic acid drug. Background Art
[0002] Because phenoxyacetic acid drugs contain phenoxyacetic acid in their main structure, they are used to develop lipid-lowering drugs, also known as anti-atherosclerotic drugs, so they are called phenoxyacetic acid lipid-lowering drugs. Their representative drugs include clofibrate, bezafibrate, fenofibrate, fenofibric acid, and pemafibrate. This type of drug accelerates the decomposition of lipoproteins by enhancing the activity of lipoprotein esterase, and can also reduce the synthesis of lipoproteins in the liver, thereby lowering blood lipids. This type of drug is easily absorbed by the intestine after oral administration. It is mainly used clinically for hypertriglyceridemia or mixed hyperlipidemia with elevated triglycerides. Its effect in lowering triglycerides is better than cholesterol. In addition to mainly exerting anti-atherosclerotic effects by correcting dyslipidemia, it can also exert anti-atherosclerotic effects by preventing blood coagulation, promoting thrombus dissolution, and reducing atherosclerotic inflammation. In clinical practice, this type of drug is often used for the prevention and treatment of atherosclerosis.
[0003] At present, there are titration methods and HPLC methods for the detection of some phenoxyacetic acid drugs, but there are still some phenoxy aromatic acid drugs that do not have efficient and convenient detection methods. Therefore, it is of great significance to develop an efficient, convenient and accurate content determination method. Summary of the invention
[0004] The present invention uses a common high performance liquid chromatograph, and conducts a series of explorations and optimizations on sample processing and chromatographic conditions according to the physical and chemical properties of phenoxy aromatic acid drugs, and provides a detection method for determining the content of a main drug in a phenoxyacetic acid drug by high performance liquid chromatography, which has the characteristics of simple operation, strong specificity, high accuracy and good durability.
[0005] The purpose of the first aspect of the present invention is to provide a method for detecting the content of the main drug in phenoxyacetic acid drugs.
[0006] The purpose of the second aspect of the present invention is to provide an application of the detection method of the first aspect of the present invention in the quality control of phenoxyacetic acid drugs.
[0007] In order to achieve the above object, the technical solution adopted by the present invention is:
[0008] The first aspect of the present invention provides a method for detecting the content of the main drug in phenoxyacetic acid drugs, comprising the following steps: preparing a test solution and a reference solution, respectively detecting the test solution and the reference solution by high performance liquid chromatography, and calculating the content of the active ingredient in the test sample by the external standard method based on the peak area and concentration of the reference solution and the peak area of the test sample, wherein the phenoxyacetic acid drugs include Pemabet.
[0009] In some embodiments of the present invention, the elution in the liquid chromatography is carried out in an isocratic elution mode, and the mobile phase is phosphate buffer-acetonitrile.
[0010] In some embodiments of the present invention, the phosphate buffer in the mobile phase contains trifluoroacetic acid, and the concentration of the phosphate buffer is 0.03-0.06 mol / L.
[0011] In some embodiments of the present invention, the phosphate buffer in the mobile phase contains 0.1 v / v% trifluoroacetic acid, and the concentration of the phosphate buffer is 0.05-0.06 mol / L.
[0012] In some embodiments of the present invention, the volume ratio of the phosphate buffer to acetonitrile is 20:70 to 50:50.
[0013] In some preferred embodiments of the present invention, the volume ratio of the phosphate buffer to acetonitrile is 30:70 to 40:60.
[0014] In some embodiments of the present invention, the flow rate of the mobile phase is 0.5 to 2 mL / min.
[0015] In some preferred embodiments of the present invention, the flow rate of the mobile phase is 0.8 to 1.5 mL / min.
[0016] In some embodiments of the present invention, the conditions of the liquid chromatography are: a chromatographic column with octadecylsilane bonded silica gel as a filler; and an ultraviolet detector with a detection wavelength of 250 to 300 nm.
[0017] In some embodiments of the present invention, the detection wavelength is 270-290 nm.
[0018] In some embodiments of the present invention, the column temperature of the liquid chromatography is 30-40°C.
[0019] In some preferred embodiments of the present invention, the column temperature of the liquid chromatography is 32-35°C.
[0020] In some embodiments of the present invention, the chromatographic column is C18 4.6 mm×250 mm, 5 μm.
[0021] In some embodiments of the present invention, the injection volume in the liquid chromatography is 45-50 μL.
[0022] In some embodiments of the present invention, the reference solution is prepared by mixing the standard with 50 v / v% to 70 v / v% acetonitrile solution, and dissolving by ultrasonication to obtain the reference solution.
[0023] In some preferred embodiments of the present invention, the reference solution is prepared by mixing the standard with 60 v / v% to 65 v / v% acetonitrile solution, and dissolving the solution by ultrasonication to obtain the reference solution.
[0024] In some embodiments of the present invention, the method for preparing the test solution is: take the sample to be tested and mix it with 50v / v%~70v / v% acetonitrile solution, and ultrasonicate for 10~20min to obtain the test solution.
[0025] In some preferred embodiments of the present invention, the method for preparing the test solution is: take the sample to be tested and mix it with 60v / v%~65v / v% acetonitrile solution, and ultrasonicate for 10~15min to obtain the test solution.
[0026] The detection method provided by the present invention can quickly and accurately determine the main drug content in phenoxyacetic acid drugs, which is convenient and fast, and greatly improves the detection efficiency. The detection method provided by the present invention has low environmental requirements, simple sample solution preparation, good solution stability, and good detection accuracy. At the same time, the method is easy to operate, meets the requirements of the drug analysis method of the Chinese Pharmacopoeia, and has important application value in aspects such as raw materials and preparation quality research.
[0027] The second aspect of the present invention provides application of the detection method of the first aspect of the present invention in quality control of phenoxyacetic acid drugs.
[0028] The beneficial effects of the present invention are:
[0029] As a Class 1 lipid-lowering drug, phenoxyaromatic acid lipid-lowering drugs have a high clinical usage rate and a wide range. Under the premise that there is no convenient detection method for some varieties, the present invention provides a detection method for determining the content of a main drug in a phenoxyacetic acid drug by high performance liquid chromatography. The present invention has the advantages of convenient operation, high reproducibility, good accuracy, etc., and can be used for the quantitative detection of the main drug component in fibrate lipid-lowering drugs, which is of great significance in drug quality control and drug safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 It is the blank solution chromatogram in Example 1.
[0031] Figure 2 It is the chromatogram of the reference substance solution in Example 1.
[0032] Figure 3 The chromatogram of the test solution in Example 1.
[0033] Figure 4 This is the chromatogram of the reference solution in Example 2 (flow rate 0.8 mL / min).
[0034] Figure 5 This is the chromatogram of the reference solution in Example 2 (flow rate 1.2 mL / min).
[0035] Figure 6 This is the chromatogram of the reference solution in Example 3 (the organic phase (acetonitrile) ratio is 30%).
[0036] Figure 7 This is the chromatogram of the reference solution in Example 3 (the ratio of the organic phase (acetonitrile) is 40%).
[0037] Figure 8 It is the chromatogram of the blank auxiliary material solution in Example 4.
[0038] Fig. 9 This is the linear test chromatogram in Example 4.
[0039] Fig.10 This is the chromatogram of the 80% accuracy test in Example 4.
[0040] Fig.11 This is the stability test chromatogram in Example 4. DETAILED DESCRIPTION
[0041] The present invention is further described in detail below through specific examples.
[0042] It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0043] In order to make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be purchased commercially.
[0044] The features and performance of the present invention are further described in detail below in conjunction with the embodiments.
[0045] Example 1
[0046] A method for detecting the content of a main drug in a phenoxyacetic acid drug comprises the following steps:
[0047] (1) Preparation of reference solution: Take an appropriate amount of Pemabet reference substance (Guangzhou Aige Biotechnology Co., Ltd., content 99.7%), accurately weigh it, add an appropriate amount of diluent (prepared by mixing water and acetonitrile in a ratio of 35:65, the same below), sonicate to dissolve it, and dilute it with a diluent to make a 5 μg / mL reference substance solution.
[0048] (2) Preparation of test solution: Place 10 tablets of Pemabet in a 200 mL volumetric flask, add an appropriate amount of diluent, sonicate for 15 min, dilute to the mark with diluent, and filter with a 0.45 μm filter membrane before injection.
[0049] (3) Determination: Perform liquid chromatography on the reference solution and the test solution using a high performance liquid chromatograph, record the chromatogram, and calculate the content of the active ingredient in the test sample using the external standard method based on the peak area and concentration of the reference solution and the peak area of the test sample.
[0050] Instrument and chromatographic conditions: Agilent 1260 high performance liquid chromatograph; chromatographic column: C18 4.6mm×250mm, 5μm, column temperature: 35°C. 0.05mol / L phosphate buffer (containing 0.1% trifluoroacetic acid)-acetonitrile (35:65) was used as the mobile phase, isocratic elution for 20min, mobile phase flow rate was 1.0mL / min. UV detector was used, detection wavelength was 280nm. Injection volume was 50μL.
[0051] The calculation formula is as follows:
[0052] C 对 =M 对 ×P 对 / Dilution multiple
[0053]
[0054] Where:
[0055] M 对 : Reference substance sample weight (mg);
[0056] p 对 : Content of reference substance (%);
[0057] A 供 : Peak area of test solution;
[0058] A 对 : Peak area of reference solution;
[0059] C 对 : Concentration of reference substance (mg / mL).
[0060] The above detection method can completely extract the active ingredients in the sample to be tested and make the main peak of the chromatogram symmetrical ( Figure 1 to Figure 3 ).
[0061] Example 2
[0062] The other conditions of this example are the same as those of Example 1, except for the flow rate of the mobile phase: the flow rates of the mobile phase are 1.2 mL / min and 0.8 mL / min, respectively.
[0063] Depend on Figure 4 and Figure 5 It can be seen that when the flow rate changes by ±20%, the chromatogram peak shape remains good.
[0064] Example 3
[0065] The other conditions of this example are the same as those of Example 1, except for the mobile phase: the volume ratio of the mobile phase of phosphate buffer (containing 0.1% trifluoroacetic acid)-acetonitrile is adjusted to 70:30 and 60:40.
[0066] The results are as follows Figure 6 and Figure 7 As shown in the figure, when the proportion of organic phase in the mobile phase changes by ±5%, the peak shape of the chromatogram remains good.
[0067] Example 4
[0068] The detection method of Example 1 was further tested for its effectiveness.
[0069] 1. Specificity of the detection method
[0070] Take 1.25 g of blank auxiliary material, put it in a 200 mL volumetric flask, add an appropriate amount of diluent, ultrasonicate for 15 min, and dilute to scale with a diluent to obtain a blank auxiliary material solution. The reference solution and the test solution were prepared by the method of Example 1, and the above solutions were tested.
[0071] The results are shown in Table 1. The blank solution and blank excipients did not produce peaks at the retention time of the target compound ( Figure 8 ) does not interfere with the detection of the target, indicating that this method has strong specificity.
[0072] Table 1 Specificity verification results
[0073]
[0074] 2. Linearity of the detection method
[0075] Reference solutions of different mass concentrations were prepared as standard solutions and measured (the concentration of the standard solution and the detection conditions were the same as in Example 1). A standard curve was drawn with mass concentration as the abscissa (x) and the corresponding peak area as the ordinate (y) to determine the linear range, regression equation and correlation coefficient of the method.
[0076] The results showed that within the range of 5.3-17.0 μg / mL, the linear correlation coefficient was r=0.9999, and the response value of Y-axis intercept / 100% concentration was ≤2.0%. The concentration and peak area showed a good linear relationship ( Fig. 9 ).
[0077] 3. Accuracy of the detection method
[0078] Three standard solutions with low, medium and high concentration levels were set respectively (80%, 100%, 120% of the target concentration, the target concentration was 10 μg / mL), and 3 portions were prepared in parallel for each concentration, for a total of 9 portions. 1.25 g of blank auxiliary material was added to each of them. The target substance was extracted and tested using the preparation method of the test solution in Example 1, and the average recovery rate and relative standard deviation were calculated.
[0079] The results are shown in Table 2 and Fig.10 As shown, it can be seen that the average recovery rate of the target is between 100.1% and 101.5%, and the RSD is 0.75%, indicating that the detection method has good accuracy.
[0080] Table 2 Accuracy verification results of the detection method
[0081]
[0082] 4. Stability of the detection method
[0083] The test solution prepared in Example 1 was placed at room temperature, and detection and analysis were performed at 0h, 1h, 2h, 4h, and 8h after preparation, and the peak area was recorded and the peak area change rate was calculated. The measurement was repeated 3 times in each time period.
[0084] Table 3 Stability results of the detection method
[0085]
[0086] The results showed that the peak area change rate of the test solution was less than 2.0% when it was placed at room temperature for 8 hours (Table 3 and Fig.11 ), indicating that the sample solution has good stability.
[0087] The embodiments of the present invention are described in detail above in conjunction with the accompanying drawings, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.
Claims
1. A method for rapidly determining the main component in phenoxyacetic acid drugs, comprising the following steps: A test solution and a reference solution are prepared, and the test solution and the reference solution are respectively detected by high performance liquid chromatography. The content of the active ingredient in the test sample is calculated by the external standard method based on the peak area and concentration of the reference solution and the peak area of the test sample. The phenoxyacetic acid drugs include Pemabet.
2. The detection method according to claim 1, characterized in that: The elution in the liquid chromatography is carried out in an isocratic elution mode, and the mobile phase is phosphate buffer-acetonitrile.
3. The detection method according to claim 2, characterized in that: The phosphate buffer in the mobile phase contains trifluoroacetic acid, and the concentration of the phosphate buffer is 0.03-0.06 mol / L.
4. The detection method according to claim 2, characterized in that: The volume ratio of the phosphate buffer to acetonitrile is 20:70 to 50:
50.
5. The detection method according to any one of claims 1 to 4, characterized in that: The flow rate of the mobile phase is 0.5-2 mL / min.
6. The detection method according to any one of claims 1 to 4, characterized in that: The conditions of the liquid chromatography are: a chromatographic column with octadecylsilane bonded silica gel as a filler; an ultraviolet detector with a detection wavelength of 250-300nm.
7. The detection method according to claim 6, characterized in that: The column temperature of the liquid chromatography is 30-40°C.
8. The detection method according to any one of claims 1 to 4, characterized in that: The preparation method of the reference substance solution is as follows: mixing the standard substance with 50 v / v% to 70 v / v% acetonitrile solution, and dissolving by ultrasonication to obtain the reference substance solution.
9. The detection method according to any one of claims 1 to 4, characterized in that: The preparation method of the test solution is: take the sample to be tested and mix it with 50v / v% to 70v / v% acetonitrile solution, and perform ultrasound for 10 to 20 minutes to obtain the test solution.
10. Use of the detection method according to any one of claims 1 to 9 in the quality control of phenoxyacetic acid drugs.
